These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

340 related items for PubMed ID: 20737140

  • 1. Increases in hip and spine bone mineral density are predictive for vertebral antifracture efficacy with ibandronate.
    Miller PD, Delmas PD, Huss H, Patel KM, Schimmer RC, Adami S, Recker RR.
    Calcif Tissue Int; 2010 Oct; 87(4):305-13. PubMed ID: 20737140
    [Abstract] [Full Text] [Related]

  • 2. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis.
    Chesnut CH, Skag A, Christiansen C, Recker R, Stakkestad JA, Hoiseth A, Felsenberg D, Huss H, Gilbride J, Schimmer RC, Delmas PD, Oral Ibandronate Osteoporosis Vertebral Fracture Trial in North America and Europe (BONE).
    J Bone Miner Res; 2004 Aug; 19(8):1241-9. PubMed ID: 15231010
    [Abstract] [Full Text] [Related]

  • 3. Significance of a decline in bone mineral density while receiving oral bisphosphonate treatment.
    Sebba AI.
    Clin Ther; 2008 Mar; 30(3):443-52. PubMed ID: 18405784
    [Abstract] [Full Text] [Related]

  • 4. Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study.
    Miller PD, McClung MR, Macovei L, Stakkestad JA, Luckey M, Bonvoisin B, Reginster JY, Recker RR, Hughes C, Lewiecki EM, Felsenberg D, Delmas PD, Kendler DL, Bolognese MA, Mairon N, Cooper C.
    J Bone Miner Res; 2005 Aug; 20(8):1315-22. PubMed ID: 16007327
    [Abstract] [Full Text] [Related]

  • 5. Regional distribution of spine and hip QCT BMD responses after one year of once-monthly ibandronate in postmenopausal osteoporosis.
    Engelke K, Fuerst T, Dasic G, Davies RY, Genant HK.
    Bone; 2010 Jun; 46(6):1626-32. PubMed ID: 20226286
    [Abstract] [Full Text] [Related]

  • 6. Ibandronate: a review of its vertebral and nonvertebral antifracture efficacy.
    Amling M, Kurth A.
    Womens Health (Lond); 2009 Sep; 5(5):467-73. PubMed ID: 19702445
    [Abstract] [Full Text] [Related]

  • 7. Oral daily ibandronate prevents bone loss in early postmenopausal women without osteoporosis.
    McClung MR, Wasnich RD, Recker R, Cauley JA, Chesnut CH, Ensrud KE, Burdeska A, Mills T, Oral Ibandronate Study Group.
    J Bone Miner Res; 2004 Jan; 19(1):11-8. PubMed ID: 14753731
    [Abstract] [Full Text] [Related]

  • 8. Which is the preferred site for bone mineral density monitoring as an indicator of treatment-related anti-fracture effect in routine clinical practice? A registry-based cohort study.
    Leslie WD, Martineau P, Bryanton M, Lix LM.
    Osteoporos Int; 2019 Jul; 30(7):1445-1453. PubMed ID: 31016351
    [Abstract] [Full Text] [Related]

  • 9. Intravenous ibandronate injections in postmenopausal women with osteoporosis: one-year results from the dosing intravenous administration study.
    Delmas PD, Adami S, Strugala C, Stakkestad JA, Reginster JY, Felsenberg D, Christiansen C, Civitelli R, Drezner MK, Recker RR, Bolognese M, Hughes C, Masanauskaite D, Ward P, Sambrook P, Reid DM.
    Arthritis Rheum; 2006 Jun; 54(6):1838-46. PubMed ID: 16729277
    [Abstract] [Full Text] [Related]

  • 10. Relationships between bone mineral density and incident vertebral fracture risk with raloxifene therapy.
    Sarkar S, Mitlak BH, Wong M, Stock JL, Black DM, Harper KD.
    J Bone Miner Res; 2002 Jan; 17(1):1-10. PubMed ID: 11771654
    [Abstract] [Full Text] [Related]

  • 11. Similar relationship between the time course of bone mineral density improvement and vertebral fracture risk reduction with denosumab treatment in postmenopausal osteoporosis and prostate cancer patients on androgen deprivation therapy.
    Pérez Ruixo JJ, Zheng J, Mandema JW.
    J Clin Pharmacol; 2014 May; 54(5):503-12. PubMed ID: 24214315
    [Abstract] [Full Text] [Related]

  • 12. Update on monthly oral bisphosphonate therapy for the treatment of osteoporosis: focus on ibandronate 150 mg and risedronate 150 mg.
    Epstein S, Jeglitsch M, McCloskey E.
    Curr Med Res Opin; 2009 Dec; 25(12):2951-60. PubMed ID: 19835464
    [Abstract] [Full Text] [Related]

  • 13. Efficacy and tolerability of once-monthly oral ibandronate (150 mg) and once-weekly oral alendronate (70 mg): additional results from the Monthly Oral Therapy With Ibandronate For Osteoporosis Intervention (MOTION) study.
    Emkey R, Delmas PD, Bolognese M, Borges JL, Cosman F, Ragi-Eis S, Recknor C, Zerbini CA, Neate C, Sedarati F, Epstein S.
    Clin Ther; 2009 Apr; 31(4):751-61. PubMed ID: 19446148
    [Abstract] [Full Text] [Related]

  • 14. Efficacy and safety of monthly oral ibandronate in the prevention of postmenopausal bone loss.
    McClung MR, Bolognese MA, Sedarati F, Recker RR, Miller PD.
    Bone; 2009 Mar; 44(3):418-22. PubMed ID: 18950736
    [Abstract] [Full Text] [Related]

  • 15. Comparison of the effects of three oral bisphosphonate therapies on the peripheral skeleton in postmenopausal osteoporosis: the TRIO study.
    Paggiosi MA, Peel N, McCloskey E, Walsh JS, Eastell R.
    Osteoporos Int; 2014 Dec; 25(12):2729-41. PubMed ID: 25074351
    [Abstract] [Full Text] [Related]

  • 16. Once-monthly oral ibandronate improves biomechanical determinants of bone strength in women with postmenopausal osteoporosis.
    Lewiecki EM, Keaveny TM, Kopperdahl DL, Genant HK, Engelke K, Fuerst T, Kivitz A, Davies RY, Fitzpatrick LA.
    J Clin Endocrinol Metab; 2009 Jan; 94(1):171-80. PubMed ID: 18840641
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Ibandronate dose response is associated with increases in bone mineral density and reductions in clinical fractures: results of a meta-analysis.
    Sebba AI, Emkey RD, Kohles JD, Sambrook PN.
    Bone; 2009 Mar; 44(3):423-7. PubMed ID: 19049913
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.